Amneal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMRX and other ETFs, options, and stocks.

About AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. 

CEO
Chintu Patel
CEOChintu Patel
Employees
8,500
Employees8,500
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
2002
Founded2002
Employees
8,500
Employees8,500

AMRX Key Statistics

Market cap
6.31B
Market cap6.31B
Price-Earnings ratio
41.26
Price-Earnings ratio41.26
Dividend yield
—
Dividend yield—
Average volume
3.45M
Average volume3.45M
High today
$20.45
High today$20.45
Low today
$19.33
Low today$19.33
Open price
$20.00
Open price$20.00
Volume
2.89M
Volume2.89M
52 Week high
$21.18
52 Week high$21.18
52 Week low
$9.56
52 Week low$9.56

Stock Snapshot

Amneal Pharmaceuticals(AMRX) stock is priced at $19.90, giving the company a market capitalization of 6.31B. It carries a P/E multiple of 41.26.

On 2026-09-27, Amneal Pharmaceuticals(AMRX) stock moved within a range of $19.33 to $20.45. With shares now at $19.90, the stock is trading +2.9% above its intraday low and -2.7% below the session's peak.

Trading volume for Amneal Pharmaceuticals(AMRX) stock has reached 2.89M, versus its average volume of 3.45M.

The stock's 52-week range extends from a low of $9.56 to a high of $21.18.

The stock's 52-week range extends from a low of $9.56 to a high of $21.18.

AMRX News

Simply Wall St 14h
How Investors May Respond To Amneal Pharmaceuticals Generic Lanreotide Launch

Amneal Pharmaceuticals received U.S. FDA approval for its lanreotide injection 120 mg/0.5 mL in a single-dose prefilled syringe, referencing SOMATULINE Depot, w...

How Investors May Respond To Amneal Pharmaceuticals Generic Lanreotide Launch
Simply Wall St 3d
Amneal Pharmaceuticals Gains FDA Nod As Fair Value Sits Higher

Advertisement FDA approval that moved Amneal Pharmaceuticals stock Amneal Pharmaceuticals (AMRX) drew fresh investor attention after the FDA cleared its gener...

Amneal Pharmaceuticals Gains FDA Nod As Fair Value Sits Higher
Nasdaq 4d
Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform

Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Amneal Pharmaceuticals (NASDAQGS:AMRX) (DB:2DT) with a Outperform recommendation....

Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

More AMRX News

Investing.com 5d
Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating - Investing.com

...

Oppenheimer initiates Amneal Pharmaceuticals stock with outperform rating - Investing.com
TipRanks 5d
Amneal Pharmaceuticals initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating and $27 price target The firm believes Amneal is at a “fundamental inf...

People also own

Based on the portfolios of people who own AMRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.